In 2013, bioMérieux celebrated both its 50th anniversary and a remarkable entrepreneurial adventure at the service of public health worldwide. With key dates noted over the pages, this year’s annual report summarizes the main steps that have marked the development of the Group, its product offering, as well as its capacity to innovate and its international development.

www.biomerieux50.com
A world leader in the field of *in vitro* diagnostics for 50 years, bioMérieux is present in more than 150 countries through 41 subsidiaries and a large network of distributors. In 2013, revenues reached €1.588 billion with 87% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the NYSE Euronext Paris market.
50 YEARS OF ENTREPRENEURSHIP

1963
Creation of BD Mérieux

1974
Acquisition of majority share in BD Mérieux renamed bioMérieux
What were the key trends in bioMérieux’s activity in 2013?

Jean-Luc Bélingard – We met the targets we set, with a solid financial performance in 2013. Sales amounted to €1,588 million, which represents growth of 4.6% at constant exchange rates and scope of consolidation, and operating income before non-recurring items reached €262 million. Once again this year, against a backdrop of global economic tensions, our results clearly attest to the competitiveness of bioMérieux and the strength of our business model. They also reflect the wisdom of a strategy based on international outreach and innovation. The scope of our global network ensures our balanced presence in mature as well as emerging countries, which confirmed their full growth potential. Thanks to our innovation programs, we launched 18 new products in 2013 and bolstered our leadership positions in both clinical and industrial microbiology.

Beyond our commercial performance and with an eye towards the future, we made a strategic acquisition in the United States with BioFire. With this acquisition, we are taking a further step in the implementation of the strategy drawn up with Alexandre three years ago and I am particularly pleased that he has taken on the role of CEO today ensuring the deployment of our long term ambitions.

In what ways was acquiring BioFire a strategic move?

Jean-Luc Bélingard – The acquisition of BioFire unquestionably represents a major step forward for bioMérieux, giving us access to a revolutionary and unrivalled technology in microbiology. This acquisition will enable us to further reinforce our leadership position in microbiology for the diagnosis of infectious diseases for the long term. This operation gives remarkable impetus to our molecular biology strategy. Thanks to our powerful commercial network, we will be able to market FilmArray®, a game-changing, high medical-value system, all over the world.

Moreover, the markets responded to this acquisition with enthusiasm. Last October, when we placed a bond issue to contribute to funding the operation, it was more than four times over-subscribed!
What advantages do BioFire’s solutions offer patients and physicians?

Jean-Luc Bélingard – Thanks to the FilmArray® system, it is possible to take a syndromic approach to infectious disease diagnostics. This system provides an exceptional opportunity to improve patient care and it represents an important medical breakthrough.

In a single test – whereas several are usually necessary – this easy-to-use system allows the rapid and simultaneous detection of the microorganism responsible for a set of symptoms, whether they are viruses, bacteria, yeasts, parasites as well as certain antibiotic resistance mechanisms. Physicians can then rapidly administer appropriate therapy to their patients to treat respiratory infections and blood infections. This, in turn, contributes to shorter hospital stays, helps curb the spread of infectious diseases, and combats antimicrobial resistance. We are also working on additional new infectious disease panels for gastrointestinal infections, meningitis, lower respiratory tract diseases, and more.

The FilmArray® system enriches bioMérieux’s high medical-value product offering.

bioMérieux celebrated its 50th anniversary in 2013. How would you describe this past half century?

Alexandre Mérieux – Looking back on the road travelled since my father created bioMérieux in 1963, we can feel proud of what we have accomplished in the area of public health. The story of bioMérieux is first and foremost a family and an entrepreneurial adventure. It is the story of the men and women who have illustrated their pioneering spirit in the service of diagnostics to fight infectious diseases. In 1963, there were fewer than 15 employees; today we are over 8,000 strong across the globe. The year the company celebrated its 50th anniversary is the same year in which we made a major strategic acquisition, BioFire, showing our capacity to project ourselves into the future in order to remain pioneers, with the same spirit of conquest.

From the outset, what have been the drivers behind bioMérieux’s actions?

Alexandre Mérieux – Our family has always had a long-term vision – made possible through our independence – and I believe this has been the basis of bioMérieux’s success, but which is also driven by a longstanding expertise in infectious diseases. We have remained pioneers in this field and, through our numerous collaborations, enriched it with our medical vision. We have successfully expanded our clinical expertise to industrial microbiology control, which is extremely important from the standpoint of disease prevention in order to protect consumers’ health.

International outreach has consistently provided a stimulus for our actions. We were present in emerging countries way ahead of the game. In March 2014, the visit to Marcy l’Etoile by the President of the People’s Republic of China is certainly a sign of recognition of our historical commitment to China, and for our achievements, over many years, working alongside the Chinese health authorities to meet their needs. For us, this country is a major bioindustrial hub. China is poised to become our second largest market after the United States and before France.
How do you envision the future?

Alexandre Mérieux – bioMérieux’s foundations are extremely solid and we can look to the future with confidence. We have a very broad product portfolio that we will continue to expand and enhance with the launch of strategic products, such as the VIRTUO™ blood culture instrument and our “smart” incubator system. We can count on the strength of our extensive international commercial network for the rollout of these products worldwide.

Our innovation policy is built on promising partnerships, and here I refer in particular to our agreement with Quanterix, which will allow us to move into a new class of ultrasensitive immuno-assays.

Our external growth policy has paid off, with all the expected synergies. For example, the acquisitions of ARGENE and, more recently BioFire, consolidate our position in molecular biology for high medical-value tests. The successful integration of AES in the area of industrial applications makes us a world leader, with one of the largest offers in a highly dynamic market.

Lastly, and most importantly, we can rely on our multicultural teams of talented individuals who, time and again, have demonstrated their potential for mobilization worldwide.

As you take over as Chief Executive Officer of bioMérieux, what is your roadmap for 2014?

Alexandre Mérieux – My new responsibilities affirm our family’s commitment to pursue bioMérieux’s development. In 2014, we will continue to implement the strategy developed three years ago with Jean-Luc Bélingard. We will follow our roadmap for a year of consolidation and investment focused on deploying our molecular biology solutions, increasing our presence in the rapidly growing industrial application market, ramping up the commercial launch of VIDAS® 3 and marketing our new clinical microbiology systems. While adhering to a policy of strict financial discipline, we will also pursue our operational initiatives by investing in our innovation programs and in our production tools, especially at our Durham plant (United States).

Since it was founded, bioMérieux has always managed to reinvent itself. Our responsiveness and capacity to adapt have allowed us to develop in a demanding and highly specialized technological environment that is constantly changing.

To accelerate the operational deployment of our strategy, 2014 will also be the year in which we implement a new organization. It is my fervent wish that this new organization should better serve our customers while driving our performance.

By giving expanded responsibilities to the regions, creating two new business units and redefining the role of the support functions, this new organization will propel our development. We intend to navigate the changes ahead with absolute respect for the culture and values to which our Company has adhered for 50 years.
There are still unmet medical needs in each of our markets.

Yet it is obvious that disease incidence, severity and impact vary from one region to the next, along with the characteristics of the patients and the resources of the country concerned. This immense diversity is something we must take into account when we design and deliver diagnostic solutions in order to continuously enhance the medical value of our products. Our goal is to improve patient outcomes globally, and our approach must also be diverse: for instance, the number of syndromes and diseases which we target, the improvement in time-to-results, or the creation of diagnostics for promoting personalized treatments.

Mark Miller
Chief Medical Officer
In vitro diagnostic tests represent just 3 to 4% of hospital expenses, yet they continue to impact 70% of medical decisions.

In vitro diagnostic tests represent just 3 to 4% of hospital expenses, yet they continue to impact 70% of medical decisions.

They play a critical role in the prevention, monitoring and control of the spread of infectious diseases, which is even more important considering that, over the last three decades, 30 new or emerging infectious diseases have been reported globally. Due to bacterial mutations, growing antibiotic resistance and weak prevention policies in some healthcare systems, century-old disease threats such as tuberculosis are reappearing just when we thought they had been nearly or completely eradicated.

In response to these global public health challenges, bioMérieux has built and developed a diversified product offering in clinical diagnostics to improve patient care and in microbiological industrial controls to ensure consumer safety.

Proven medical value

Its expertise in infectious diseases has propelled bioMérieux to global leadership in clinical microbiology diagnostics and industrial microbiology controls, a position sustained by high medical-value products. Thus, for over 70% of its sales the Company holds two number one positions worldwide. Many different parameters demonstrate the medical value of a diagnostic tool. A simple test for early screening of sore throats allows the detection of a group A streptococcal infection, permitting suitable treatment to be prescribed, which in turn decreases the unjustified use of antibiotics. In the event of a more serious disease such as sepsis, being able to rapidly detect a potential case and identify the causative bacterium and its resistance to antibiotics, enables appropriate therapy. The prudent use of antibiotics is an essential part of controlling antibiotic resistance and decreasing hospital stays and associated costs.

PRODUCTS HIGHLIGHTS

+4.6% GROWTH IN SALES at constant exchange rates and scope of consolidation

THE ACQUISITION OF BioFire gives access to its FilmArray® system, a revolutionary molecular biology technology

18 NEW PRODUCTS launched for clinical and industrial applications
bioMérieux applies the same medical vision to industrial microbiology controls. Ensuring the microbiological quality of agri-food, cosmetic and pharmaceutical products during manufacturing and prior to commercialization by detecting potential pathogens helps protect the health of consumers.

**Contributing to the efficiency of healthcare systems**

bioMérieux’s products also respond to other challenges in connection with ever-changing healthcare systems. Mature countries and emerging countries present two distinct trends of laboratory consolidation and decentralization. For reasons of cost and efficiency, the accelerated consolidation of laboratories and reimbursement pressures encourage the development of multiplex and automated tests, providing a way to ensure uniform quality. On the other hand, policies to decentralize healthcare services require the development of robust and user-friendly systems that operate as closely as possible to the communities they serve.

**A new franchise to serve public health**

bioMérieux lives up to its commitment to serve public health by protecting communities against infectious diseases through clinical diagnostics and through solutions for the agri-food, pharmaceutical and cosmetics industries. The creation of the bioMérieux Veterinary Franchise in 2012 is consistent with our approach as it is estimated that 70% of emerging infectious diseases globally are zoonoses, i.e., transmitted to humans by an animal vector.
In clinical applications, bioMérieux’s sales rose by 3.5% in 2013 at constant exchange rates and scope of consolidation.

Microbiology, our core business, represented 50% of sales, showing growth of nearly 3%. These results were driven by sales of reagents (up 4.5%), led in particular by the performance of the VITEK® product range for automated microbial identification and antibiotic susceptibility testing, and more recent FMLA® solutions. Immunodiagnostics increased 3.5%, boosted by the strength of the VIDAS® product range, which experienced organic growth of nearly 6%.

Molecular biology benefitted from the integration of the ARGENE® ranges (+31%). One of the most dynamic growth performances amongst bioMérieux’s product ranges, it recorded total growth of 9%.

A decisive year in molecular biology
With the acquisition of 100% ownership of BioFire Diagnostics, announced in September 2013 and finalized in January 2014, bioMérieux took a very important step forward in molecular biology.

Since it was founded in 1990, this U.S.-based company has been at the cutting edge of technological and medical progress in the field of molecular biology, with a portfolio containing over 90 patents. FilmArray®, its flagship product, has introduced a new market standard and revolutionized the molecular diagnosis of infectious diseases, enabling clinicians to adopt a syndromic approach to these diseases. This new medical approach is based on analyzing a syndrome (a set of symptoms) and, in a single test, identifying organisms causing the disease, whether they are viruses, bacteria, parasites or fungi. With around 600 systems already operating in customers’ laboratories, the installed base is undergoing strong growth that attests to the success of FilmArray® in the United States, where it meets the needs of decentralized hospital laboratories. Sales of FilmArray® reached $42 million in 2013. The rapid development of BioFire should act as a key growth driver for bioMérieux in the coming years.

With this acquisition, bioMérieux consolidates its molecular biology...
offering to meet the needs of the two major categories of molecular biology laboratories:

- FilmArray® brings speed, flexibility and ease-of-use to support the syndromic approach. This platform meets the needs of decentralized hospital laboratories in emergency situations and at the patient’s bedside.
- A comprehensive automated solution for centralized and reference laboratories features three modules: first, the bioMérieux easyMAG® sample purification platform, whose solid market positioning (with an installed base of over 1,200 instruments) will be further strengthened with the upcoming launch of a new generation; second, bioMérieux will also offer – thanks to the recent agreement with Life Technologies – Applied Biosystems 7500

We could not have found a better partner than bioMérieux, world leader in microbiology.

This is an especially exciting next step in BioFire’s evolution. bioMérieux’s international commercial network will further boost sales of our flagship product, FilmArray®, outside the United States, while we continue to support our customers in the United States Department of Defense and Allied Forces. In addition, bioMérieux’s unique know-how in the field of infectious diseases will contribute to the development of new panels, creating very attractive prospects for the future.

Kirk Ririe,
Chief Executive Officer and Founder of BioFire

The FilmArray® instrument uses a simple, rapid technology that delivers results in one hour instead of several days currently with traditional methods so that patients can receive improved, rapid and personalized care. In 2013, the FilmArray® menu comprised two test panels: the respiratory panel and the sepsis panel, both of which are CE-marked and approved by the Food and Drug Administration (FDA).

For upper respiratory infections, FilmArray® tests for 17 viruses and 3 bacteria; it is the only panel of its kind to test for bacteria and viruses simultaneously, thus removing the barriers between different diagnostic techniques.

For sepsis, on the basis of a positive blood culture, the FilmArray® panel tests for Gram-positive and Gram-negative bacteria as well as 3 antibiotic resistance genes using a unique medical approach.

In addition, in May 2014, BioFire received U.S. FDA 510(k) clearance for its gastrointestinal infection test panel. FilmArray® can test for numerous pathogens: bacteria, viruses and parasites from a sample requiring minimal preparation.
instruments, among the most popular thermocyclers used worldwide; and lastly, bioMérieux provides a broad range of molecular biology tests with ARGENE®, one of the most comprehensive ranges on the market for the diagnosis of infectious diseases associated with immunocompromized persons and patients with respiratory infections and meningo-encephalitis.

VITEK® MS, a pioneer in the United States

The VITEK® MS platform, a mass spectrometry system for the rapid detection of almost 200 different microorganisms, was granted CE marking in 2011. It was granted U.S. FDA 510(k) clearance in August 2013 for broad clinical use, covering a large number of microorganisms.

To date, VITEK® MS is the only FDA Cleared MALDI-TOF microbial identification system for Gram-positives, Gram-negatives and yeasts, routinely available in the United States. The Cleveland Clinic, which was ranked the fourth best hospital in America and number one in
cardiovascular diseases according to the rankings published by U.S. News & World Report’s “2013-14 Best Hospitals,” named the MALDI-TOF technology as one of the Top Ten Breakthrough Medical Technologies of 2013.

**VIDAS®, an ongoing success**

The most widely used immunoassay system in the world, VIDAS®, continues its upward trajectory. VIDAS® 3, the new generation of VIDAS®, got off to a promising start after receiving CE marking in June 2013. VIDAS® 3 features enhanced automation, with a pre-analytical section, improved traceability and new software capabilities, as well as a quality control program in compliance with laboratory certification standards. With growth of 5.8% in 2013, this product range has leveraged a strong position in emerging markets where its flexibility, reliability and ease-of-use are especially well-adapted, and in high medical-value testing, especially for the measurement of procalcitonin (PCT). The share of high medical-value emergency testing has grown from 17% of the franchise’s sales in 2007 to 45%. With 28,000 instruments used by clinical laboratory professionals, VIDAS® represents the largest installed base of automated immunoassay system in the world.*

In 2013, the VIDAS® menu was enriched with the launch of:

- **VIDAS® 25 OH Vitamin D Total** for the measurement of vitamin D levels. This test provides extremely precise and rapid results to clinical laboratories (within 40 minutes).
- **VIDAS® C. difficile GDH**, for the detection and control of *Clostridium difficile* infections, the primary cause of healthcare-associated infectious diarrhea. With this launch, bioMérieux presents the broadest offer of solutions for the diagnosis of *C. difficile*, adapted to all laboratory structures, patient conditions and clinical needs. Both these new tests are developed and produced at bioMérieux’s Marcy l’Etoile site in France.

The **VIDAS® B.R.A.H.M.S PCT™** parameter, the star of the immunoassays range, is a confirmed success used in emergency departments as a diagnostic tool for the monitoring, prognosis and treatment of severe bacterial infections.

**Two new specialized franchises**

Keeping pace with new developments in the Company’s markets by diversifying its business activity, bioMérieux created two specialized franchises in 2013.

- The first new franchise, established in Shanghai, is dedicated to the development and commercialization of rapid tests at reduced prices, tailored to the needs of emerging countries and the challenges of neglected tropical diseases. The inauguration of this new range featured two tests: the launch of **VIKIA® Malaria Ag Pf/Pan**, the first test in a panel currently under development for
tropical diseases; and WHO pre-qualification of the VIKIA® HIV 1/2 rapid test for the detection of HIV 1 and 2 antibodies in HIV infections, giving bioMérieux access to new markets.

→ The second franchise is dedicated to personalized medicine and companion tests, which respond to the pharmaceutical industry’s growing need for biomarkers associated with specific therapies. These tests help direct treatment for “responsive” patients, thus enhancing therapeutic efficacy. The companion diagnostic test THxID™ BRAF, which received CE marking, is now being commercialized in the United States. It is intended for patients with melanoma whose tumors carry the BRAF V600E mutation for possible treatment with GlaxoSmithKline (GSK) Tafinlar® (dabrafenib), as well as patients whose tumors carry the BRAF V600E or V600K mutation for possible treatment with Mekinist® (trametinib).

**An expanded services offering**

To support the evolving role of lab professionals and empower labs to meet new performance, cost containment and management challenges, bioMérieux continued to enrich its high value-added services offering in 2013 with bioMérieux Performance Solutions™. In addition to training in the laboratory setting, since 2013, customers may choose from various remote training options via an online platform. This e-learning offering, intended for biologists and lab technicians, focuses on the use of bioMérieux products as well as scientific topics and management challenges. ▶

---

**PRODUCTS**

**2005**
- NucliSENS® easyMAG®
  - automated platform for sample preparation and extraction of nucleic acids

**2007**
- DiversiLab®
  - strain genotyping platform for bacteria and fungi
For several years, public opinion and regulatory authorities have focused increasingly on food safety and the risk of contamination of consumer products.

The primary – and powerful – growth driver of the industrial microbiology market is quality control regulation of agri-food and pharmaceutical products.

The public, as well as health authorities, are increasingly demanding when it comes to microbiological safety. Such a context has a positive overall effect on the development of even stricter control practices to ensure the safety of consumers.

Nicolas Cartier,
Corporate Vice-President, Industrial Microbiology Unit

INDUSTRIAL MICROBIOLOGICAL CONTROL

With about 21% of market share, bioMérieux is the world leader in the field of industrial microbiological control,
an estimated €1.6 billion market. Against this backdrop, sales in industrial microbiology increased by 6.8% to represent 21% of the Group’s business activity in 2013. With 22% growth in emerging countries, this activity has successfully leveraged bioMérieux’s global position and broad product offering.

In 2013, the first full year after AES and bioMérieux joined forces, the combination of the best of both companies delivered promising results.

Successful integration of the AES CHEMUNEX lines

Finalized in 2012, the acquisition of AES CHEMUNEX, which at the time was ranked fifth worldwide in the field of industrial microbiology control, propelled bioMérieux to the position of global leader in agri-food applications.

The CHEMUNEX® range of cytomtery systems confirmed its potential, ending the year with double-digit growth. The agri-food, pharmaceutical and cosmetic industries value this technique for the rapid, continuous detection of microorganisms during the production process.

The AES Blue Line™ of laboratory instruments also showed rapid growth in industrial microbiological control laboratories.

Instrument sales at the fore

The industrial microbiology activity has been driven by sales of the VITEK® and TEMPO® instruments, which have recorded double-digit growth. Reagent sales have also been strong.

TEMPO® Aerobic Count, introduced in 2013, is representative of a new generation of tests that
are faster and less impacted by the food sample type. Already a number of customers in the United States have expressed their interest in this test, which enumerates total bacterial flora in food and environmental samples in as little as 24 hours. It received AOAC Research Institute (RI) approval even before its commercial launch.

Reagents in the VIDAS® line also performed remarkably well, stimulated by the AOAC international approval of certain tests, such as VIDAS® UP Listeria and VIDAS® Listeria monocytogenes Xpress, demonstrating the reliability and importance of this complete screening solution for Listeria, a pathogenic bacterium that is widespread in the environment and may be found in certain food products.

Veterinary diagnostics off to a good start

Created in 2012, the bioMérieux veterinary franchise delivered solid results in its first year. In 2013 it developed an ambitious R&D strategy focused on fighting antimicrobial resistance in farm animals as well as on fertility and animal reproduction.

THIS YEAR’S SUCCESS STORIES

**CO-DEVELOPMENT**

within the scope of a research partnership between bioMérieux and L’Oreal, of a specific cytometry application adapted to cosmetic product manufacturing processes.

**CHEMUNEX® FLOW CYTOMETRY SOLUTION**

selected by Mengniu, leader in the Chinese dairy industry, with an initial contract for 20 cytometers.

**FOR ITS 10TH ANNIVERSARY,**

the BioBall® range used for quality control of microbiological analytical methods has outstripped market growth.

**VIDAS® UP LISTERIA & VIDAS® LISTERIA MONOCYTOGENES XPRESS**

were both winners, having been simultaneously granted AOAC International Official Methods of Analysis (OMA) approval. This unprecedented double approval will be followed by a third, for the VIDAS® UP Salmonella (SFT), which is recognized for its exceptional sensitivity. Salmonella is a bacterium that causes salmonellosis, one of the most common intestinal infections worldwide.

**DILUMAT™**

automated system to weigh and dilute industrial samples

**VIDAS® 3**

the new generation of the automated immunoassay platform

**MASTERCLAVE®**

automated dispenser of culture media
Innovation occurs at the point where an idea meets its market. When our innovation teams work on new approaches, their mission is to not only think in terms of technology but first and foremost in terms of potential products.

Alain Pluquet
Chief Technology Officer
Corporate Vice President, Innovation and Systems Unit
Internationalization, targeted acquisitions and multi-disciplinary collaborations are the key ingredients in bioMérieux’s approach to innovation.

The Company devotes nearly 12% of its sales revenue, amounting to €186 million in 2013, to developing the products that will serve tomorrow’s public health needs.

Nearly 70 research and development programs are being carried out in France, the United States and China. Over 1,000 employees based at 17* R&D sites across the globe are actively collaborating and capitalizing on shared experience to focus primarily on developing platforms and expanding menus in the field of infectious diseases as well as certain cancers and cardio-vascular diseases.

As a great believer in open innovation, bioMérieux’s priority is to develop strategic collaborations with external partners, reflected today in 25 collaborative agreements and four joint research units with public and private life sciences groups.

The innovation strategy followed by bioMérieux pursues two objectives:

- strengthening the medical value of solutions offered to clinicians as well as to industrial microbiological control laboratories;
- helping laboratories to improve workflow efficiency and productivity.

In 2013, investment in R&D increased by 10% compared with the previous year, at constant exchange rates, reflecting an especially rich portfolio of projects under development with a focus on key priority challenges:

- The high medical value of diagnostic tests in response to the market’s unmet needs;
- The increased demand for automation of microbiology laboratories, in order to optimize workflow, from sample preparation to inoculation and incubation of culture media to results analysis.

Conclusive clinical study results for the VIRTUO™ platform

Under development at bioMérieux’s Saint Louis, Missouri (U.S.) site, VIRTUO™ is an automated blood culture instrument intended to fully automate the management of blood culture bottles for use by all operators. The enhanced level of automation of this new platform furthermore allows for more rapid alerts in the event of sepsis detection. Clinical studies conducted with success in laboratories worldwide should make a gradual European commercial launch possible in mid-2014.

---

* As of January 2014, bioMérieux has 18 R&D centers including the BioFire site located in Salt Lake City, Utah (U.S.), which has become bioMérieux’s principal site for the development of molecular biology activities.
bioMérieux’s new Smart Incubator System developed in partnership with Europe’s largest clinical microbiology laboratory

Developed as part of the Full Microbiology Laboratory Automation (FMLA®) offer, bioMérieux’s smart incubator, based on innovative imaging technology, is designed to automate the handling of inoculated culture media, their incubation as well as the visualization of results. It will include Myla® middleware, which automatically pilots all laboratory tasks and gives the microbiologist access to all relevant information with full traceability.

With this new instrument included in the FMLA® offering, bioMérieux will take another step towards full automation of microbiology laboratories.

In late 2013, a prototype incubator was installed to undergo validation by a major European clinical microbiology laboratory, which handles an average of 4,500 samples daily. The first systems are expected to be installed in the second half of 2014.

Syndromic approach: major strides with BioFire

bioMérieux aims to develop new diagnostic tools that support the syndromic approach to guide the physician’s decisions as early as possible. The syndromic medical approach is based on analyzing a syndrome or a set of symptoms and, in a single test, identifying the disease-causing organisms responsible for this syndrome, whether they are viruses, bacteria, parasites or fungi. Once the patient has been admitted, these very broad diagnostic panels allow rapid testing, in just one hour, to quickly determine the most appropriate care. The acquisition of BioFire brings promising prospects for bioMérieux in this field.
The first commercially launched solution with the FilmArray® molecular biology platform is a respiratory panel that tests for 17 viruses and 3 bacteria. The platform, which has obtained CE marking and FDA clearance, delivers results in less than one hour.

In June 2013, BioFire obtained FDA approval for a blood culture identification panel that identifies 24 pathogens and 3 three antibiotic resistance genes. In February 2014, an application was submitted to seek FDA approval for the commercialization of a third panel*, for the identification of viruses, bacteria and parasites that cause gastro-intestinal infections. This submission follows a clinical study conducted successfully on over 1,500 samples in several different U.S. hospitals. R&D synergies between bioMérieux teams in Grenoble (France) and BioFire teams in Salt Lake City, Utah (U.S.) should lead to the development of additional panels, notably for the detection of meningitis (with clinical studies conducted in spring 2014).

With FilmArray®, bioMérieux expects to be able to detect over 70 disease agents by 2016.

Ultrasensitive immunoassays: ongoing trials

Within the scope of a partnership concluded in late 2012, bioMérieux and Quanterix, a U.S.-based company, collaborated in 2013 in the field of ultrasensitive and multiplex immunoassays. bioMérieux will have worldwide exclusive rights to use Quanterix’s SIMOA platform for diagnostics in clinical laboratories and for industrial applications. Based on a digital approach that enables detection of a signal from a single molecule of a labelled analyte, SIMOA technology is far more sensitive than conventional analog-based technologies. In 2013, a first demo version of the automated instrument was installed.

PERSONALIZED MEDICINE

bioMérieux signed an exclusive agreement with Gilead Sciences Inc., a biopharmaceutical company specialized in innovative therapeutics for unmet medical needs, to co-develop an assay on the VIDAS® platform that may be a potential companion diagnostic of a Gilead drug candidate.

CONCLUSIVE CLINICAL STUDY RESULTS FOR VIRTUO™

Clinical studies of the VIRTUO™ platform under development at bioMérieux’s Saint Louis, Missouri (U.S.) site, were successfully conducted in laboratories worldwide and should allow a gradual European commercial launch in mid-2014.

* This panel received FDA 510(k) clearance in May 2014 for its commercialization on the US market
When innovation comes from emerging countries

Initiated by emerging countries for emerging countries, a reverse innovation project was introduced in China in 2013 based on local needs identified in Asia and Latin America. The purpose of this project is to launch diagnostic systems at reduced cost that are capable of identifying and characterizing the major mechanisms of antibiotic resistance. These tests must be usable by untrained technicians in laboratories located in remote areas, using culture media that can be stored at room temperature, and systems for accessing results on cell phones. The Company plans to manufacture these new products in China at the Shanghai site.

New information management services

With 50 years of experience in microbiology, bioMérieux is undertaking the systematic digitization of its knowledge resources, such as its culture collection containing over 80,000 references. The strain library, called Biopedia, provides a basis for the development of new “content-oriented” services today. The launch of a mobile application currently under development will give bioMérieux customers access to a large portion of the information contained in the culture collection.

“BioFire’s FilmArray® allows fast, comprehensive, and easy diagnosis of over 70 different pathogens that cause life threatening illness.

FilmArray® uses a “syndromic approach” to the molecular diagnosis of infectious disease. In syndromes such as respiratory infections, sepsis, and gastrointestinal infections, many different organisms can cause very similar symptoms. FilmArray®’s multiplex capability allows simultaneous testing for the many different kinds of pathogens - bacteria, viruses, fungi and parasites - that cause these syndromes. In one hour the doctor can know the underlying cause of the disease and quickly prescribe the appropriate treatment. By getting the patient on the right treatment faster, FilmArray® reduces costs and improves health.”

Randy Rasmussen, Corporate Vice President, Molecular Biology

2011
- Second joint research laboratory set up with Hospices Civils de Lyon in cancer medicine

2012
- Partnership with Quanterix for the development of a new generation of ultrasensitive, multiplex immunoassays

2014
SINCE INFECTIOUS DISEASES KNOW NO BORDERS, BIOMÉRiEUeX HAS ALWAYS SOUGHT TO MAKE ITS DIAGNOSTIC TESTING TOOLS AS WIDELY AVAILABLE AS POSSIBLE ACROSS THE GLOBE.
ts position as a pioneer in emerging countries – first and foremost China, Brazil and India – and its network of international subsidiaries, which bring it closer to its markets, provide the foundation of the Company’s global strength today.

▶ A resilient model
In a context of economic instability, bioMérieux’s worldwide network, covering more than 150 countries through 41 commercial subsidiaries, is a vital asset, today more than ever. As a leading driver of growth and competitiveness, this network enables the Company to adapt to the fluctuations in certain geographic areas while seizing the opportunities that arise in other regions.

In 2013, emerging markets confirmed their powerful role as drivers of organic growth for the Group. They continued to deliver very attractive market dynamics, taking advantage in particular of the implementation of healthcare system reforms and the rising purchasing power of the middle classes, as well as sustained demand from microbiology laboratories. At year-end, emerging countries accounted for 31% of the Group’s sales, with organic growth of more than 12%.

Internationally, sales of industrial applications experienced a robust increase, in particular in the United States (+9%) and emerging markets (+22%).

▶ A year of contrasts
In 2013, the Company showed commercial efficiency and strengthened its position, particularly in the accelerating North American market, with organic growth of 4.8%. In contrast with Northern Europe, Southern European countries, continue on a downward trend, but show encouraging signs of stabilization.

Starting mid-year, heightened volatility in...
the exchange rates of certain currencies against the euro (Turkish lira, Indian rupee, Japanese yen and the Argentinian peso) prompted the Group to adopt a particularly cautious approach, seeking to adjust its commercial strategy in an effort to limit the impact of these adverse currency effects.

Two areas of development
Emerging markets and more mature markets continue to provide sources of varied opportunities for bioMérieux. Accelerated laboratory consolidation and the resulting drive for greater efficiency, both in Europe and the U.S., created excellent opportunities in microbiology for both partially and fully automated solutions. In a number of emerging countries, VIDAS® remains the preferred solution thanks to its reliability and ease-of-use.

HIGHLIGHTS

+11.6%
THE ASIA PACIFIC REGION
records the strongest organic growth in 2013

+22%
FOR INDUSTRIAL APPLICATIONS
in emerging countries

OVER 100 DISTRIBUTORS
BY YEAR-END 2013
Expansion of the bioMérieux commercial network in Russia and China

COMMERCIAL LAUNCH OF VITEK® MS
IN THE UNITED STATES

CE MARKING FOR VIDAS® 3
IN JUNE 2013
"Given the recent World Health Organization’s (WHO) report on the urgency for addressing antimicrobial resistance, getting clinically relevant diagnostic information to the clinician in faster time frames can help minimize antibiotic misuse and/or overuse.

Our unique syndromic approach puts the patient diagnosis as the focus to address the threat of multi-drug resistant organisms and the rise of sepsis. We believe that innovative solutions such as VIDAS®, B.R.A.H.M.S PCT™, VITEK® 2 and VITEK® MS for rapid ID/AST, Myla® for advanced information management and Workflow Optimization Services for the enhancement of laboratory efficiency will help microbiology labs prepare for the future and contribute to improve antimicrobial stewardship."

"We have performed well especially considering Brazil’s moderate economic growth and the fact that the World Cup has been a priority focus for investment. Sales growth was driven by industrial applications, thanks in particular to the integration of the AES lines for the agri-food business, and to our solutions for the pharmaceutical industry.

VIDAS® sales received a strong boost when the system was selected by the world’s leading poultry exporter. The year’s success stories for clinical applications include a very good evolution on identification and antibiotic susceptibility testing due to capital sales to the private sector and supplying more than one million VIKIA® HBsAg rapid tests to the Ministry of Health for hepatitis B virus screening, as well as rising sales of tests to diagnose respiratory infections."

---

Manuel Mendez  
Executive Vice President and General Manager, Americas

Pedro di Rocco  
General Manager bioMérieux Brazil
"bioMérieux is a key player in Italy when it comes to using mass spectrometry to rapidly identify microorganisms and measure procalcitonin for the early diagnosis of severe bacterial infections in emergency departments.

In 2013, we signed a new extended territory agreement with our distributor that gives us access to the microbiology laboratory market in southern Italy and Sicily. We have been extremely pro-active in promoting our solutions for the detection of healthcare-associated infections, and feedback from the medical community has been very enthusiastic.

Lastly, for industrial applications, the TEMPO® range was chosen by the food group Ferrero, marking a major accomplishment in 2013."

Stathis Chorianopoulos
Managing Director Italy & Greece

"In China, building and equipping public hospital facilities near the communities they serve is an essential part of the deployment of the healthcare system currently underway. For instance, in the next three years over 2,000 public hospitals will purchase bacteriological testing systems. Reagent sales have been bolstered by incentives to encourage the prudent use of antibiotics.

In 2013, bioMérieux continued to increase its market share. Among this year’s major achievements, I would cite the rise in the number of distributors – which has reached 74 – and the commercialization of VITEK® MS, the only mass spectrometry system available on the market today. I would also include the local production of eight million ready-to-use culture media as well as the success of our flow cytometer solutions for the dairy industry."

Pascal Vincelot
VP Commercial Operations Greater China
North America: business is picking up

North America remains, by far, the leading diagnostics market worldwide, representing 22% of consolidated total sales for bioMérieux. After a challenging year in 2012 marked by a significant base effect, 2013 showed global growth of 4.8%. In clinical applications, reagent sales accelerated (+6%) due, in particular, to the VIDAS® B.R.A.H.M.S PCT™ test for the assessment of sepsis risk in intensive care units, which continues to win over new hospital and reference laboratory customers.

The launch of VITEK® MS, the first mass spectrometry system to be cleared by the U.S. Food and Drug Administration (FDA), opens up new and promising opportunities in clinical microbiology laboratories. Industrial applications in the U.S. record robust growth of 9%, bolstered by reagent sales and the sustained momentum of TEMPO® and VITEK® as well as synergies with AES instruments, in particular, the AES Blue Line™.

Asia Pacific: leading growth driver

As the largest contributor to overall growth of the Group’s business activity, the Asia Pacific region represented 19% of bioMérieux’s consolidated total sales by year-end 2013. This region demonstrated the strongest organic growth, at 11.6%, a performance led primarily by a vigorous market in China, where sales were up 25%, driven by the expansion of its network of distributors and the success of VITEK®, VIDAS® and industrial applications (+32%). India also reported brisk growth of 17%. In a depressed market, Japan ended the year with a respectable performance (+3%).

Europe: stability

Although regional contrasts remain, the situation in Europe improves with signs of a slight stabilization. Sales performed very satisfactorily in Northern Europe, particularly in Germany and the United Kingdom.

In France, however, the ongoing consolidation of microbiology laboratories continues to dampen sales of VIDAS® immunoassays. Following a slowdown in sales of industrial applications in the first half, sales of quality control for agrifood products picked up significantly in the second half of the year.

The macro-economic environment remains uncertain in Southern Europe, where a decline in sales slowed slightly, showing encouraging signs for more than two years now.
**Turkey, Middle East, Eastern Europe and Africa: double-digit growth**

In Turkey, the leading market in this region, sales were robust despite a tense economic and political situation, with an 11% increase in 2013. In Russia, sales showed excellent growth resulting from the reorganization of the local distributor network over the last two years. The Middle East/Africa regions continue to report brisk growth driven by strong clinical microbiology demand.

**Latin America: dynamic growth**

Sales in Latin America (representing 8% of the consolidated total) increased by 6.2%, with 7% for reagents. Subsidiaries in Mexico and Colombia exhibited dynamic growth of 14% and 8%, respectively. Despite being weakened by slowed growth and inflation, Brazil nonetheless ended 2013 with a rise in sales of over 4%, led by solid gains in rapid tests and industrial applications.

---

**THIS YEAR’S SUCCESS STORIES**

**VIDAS®, AN INTERNATIONAL SENSATION**

VIDAS® is the bioMérieux product line most widely represented internationally, with China as its 3rd largest market.

**FOCUS ON REAGENTS**

Launched in 2013, the “Operational Efficiency” international program puts the accent on installed instrument base cost-effectiveness by increasing sales of reagents.

**VITEK® MS ADOPTED BY A REFERENCE NETWORK**

The VITEK® MS version designed for industrial applications was selected by EMSL Analytical, a leading U.S. microbiology testing laboratory network.

**BIOMÉRIEUX, A MEMBER OF G5 SANTÉ IN CHINA**

Founded by the leading French companies in the healthcare sector in China, this club aims to supply local health sector players with a comprehensive range of products and services from French companies, tailored to their specific needs.
Since 1967
Support to the Fondation Mérieux actions
in the fight against infectious diseases in developing countries

ATE
SIBILITY

SOCIETAL / SOCIAL / ENVIRONMENTAL
bioMérieux’s responsibility as a corporate citizen is closely tied to the very nature of its business.

As a major player in the field of *in vitro* diagnostics, the Company’s model for development is rooted in its commitment to serve global public health. This longstanding commitment creates responsibilities that bioMérieux embraces across its areas of expertise, with a triple focus:

- **Responsibility to society**, by improving access to diagnostics for as many people as possible worldwide and by seeking to respond to priority public health needs,
- **Responsibility to the workforce**, by creating a safe and healthy working environment and professional development opportunities for employees, as well as by striving to meet the highest standards of ethical behavior and solidarity with bioMérieux’s partners,
- **Responsibility to the environment**, by reducing and controlling the environmental footprint left by the Group’s activities.

### RESPONSIBILITY TO SOCIETY

#### Support to the Mérieux Foundations in developing countries

True to its public health missions and as part of its corporate sponsorship approach, bioMérieux supports the work of the Fondation Mérieux and the Fondation Christophe and Rodolphe Mérieux. In 2013, the Company’s contributions to sponsorship activities amounted to a total of €2.557 million including €1.814 million for the above mentioned foundations. In the field, these two independent family foundations fight infectious diseases affecting developing countries, in particular by improving their clinical biology capabilities. The Fondation Christophe and Rodolphe Mérieux, under the aegis of Institut de France, is the reference shareholder of Institut Mérieux. A portion of
its resources comes from dividends paid by the Institut Mérieux, whose primary resources are the dividends of its daughter companies, bioMérieux in particular.

Thanks to the support of bioMérieux and other partners, the foundations have successfully carried out a number of initiatives in developing countries:

- Today they are active in 8 countries: Haiti, Mali, Madagascar, Lebanon, Tajikistan, China, Laos and Cambodia. Projects are underway in Bangladesh and Brazil. Their concerted efforts have led to the creation of 8 reference laboratories, the Rodolphe Mérieux Laboratories, which are dedicated to training biologists, diagnosing diseases specific to these countries and supporting applied research. A number of clinical laboratories have also been renovated and their personnel have been trained.

- Through the Christophe Mérieux Prize, worth €500,000, the Fondation Christophe and Rodolphe Mérieux encourages research in developing countries. This major scientific prize, conferred for the seventh time in 2013, was awarded to Dr. Valerie Mizrahi, Director of the Institute of Infectious Disease and Molecular Medicine and professor at the University of Cape Town in South Africa, to encourage her research on tuberculosis, the leading cause of infectious disease-related mortality worldwide, particularly in South Africa.

**Products adapted to the needs of low-resource countries**

Determined to ensure that diagnostic tools are within the reach of the emerging and developing countries, bioMérieux works to develop products to screen for global and tropical infectious diseases. Launched in January 2013, VIKIA® Malaria Ag Pf/Pan completes our current offer for rapid diagnostic tests which already includes HIV and Hepatitis B. In December, VIKIA® HIV 1/2, for the detection of anti HIV 1 & 2 antibodies in the case of HIV infections, received WHO pre-qualification, opening up new markets for this test.
Committed to the fight against bacterial resistance

Organized at the initiative of bioMérieux in June 2013, the World Healthcare Associated Infections (HAI) Forum brought together over 70 internationally-renowned experts in the field of antimicrobial resistance and healthcare-associated infections, who met in Annecy (France) for the Forum’s fourth edition. The incidence of antimicrobial resistance is rising sharply, and just a few days earlier the G8 Summit had recognized this phenomenon as one of the major public health challenges worldwide. The World HAI Forum experts established 10 priorities to address the challenges of antimicrobial resistance. bioMérieux has committed to support two of the priority actions within 18 months. The Company thus contributes to worldwide surveys for the global measurement of antibiotic use and resistance. It moreover participates in conducting a multi-center study on the long-term benefits of prudent antimicrobial use.

Towards an even more personalized and rapid diagnosis with BIOASTER

Institut Mérieux is a founding member of BIOASTER, a technological research institute specialized in infectious diseases, created within the scope of the French government’s program of investments for the future. BIOASTER, which brings together industry and public research organizations, entered its operational phase of activity in 2013. As part of this privileged partnership, bioMérieux contributes its active support to several research programs focusing on the identification of infectious diseases, healthcare-associated infections and antimicrobial resistance.

International mobilization against superbugs

At the initiative of bioMérieux, 70 experts on antimicrobial resistance and healthcare-associated infections from 31 countries came together for the fourth edition of the World HAI Forum, where they drew up a list of 10 priority actions.

Investing in a fund for innovative French start-ups

bioMérieux has invested €1 million in ATI (Amorçage Technologique Investissement), a fund dedicated to French start-ups developing products and services based on significant technological innovations in areas covered by the French Atomic Energy Commission (CEA).

50 years, 50 initiatives

In celebration of bioMérieux’s 50th anniversary, the Group’s different sites carried out 50 local solidarity initiatives over the course of the year. Fifty teams based in 20 countries organized actions ranging from solidarity sports events to environmental initiatives, donations and local mutual aid initiatives.

bioMérieux supports the mobile HIV council and testing project in Benin and Togo, launched in 2013 by SANTE EN ENTREPRISE (SEE)*.

This program aims to raise awareness among local companies and communities regarding HIV council and testing, offer free HIV testing using rapid tests and support the medical and psychosocial care of people tested positive. bioMérieux supports this project by providing free VIKIA® HIV 1/2 tests and training trainers to use this rapid test.

* SEE is an operational platform that implements inter-business cooperation in coordinating high-impact HIV, malaria, and chronic illness awareness actions that touches employees, their families and the general public. It operates internationally.
We are fortunate to have a strong corporate culture and meaningful social dialogue linked to bioMérieux’s entrepreneurial family tradition.

The celebration of our 50th anniversary demonstrated how deeply attached our employees are to the Company. I was impressed by the number of volunteers who took part in open house events, by all those who spontaneously contributed their time, and by our employees’ enthusiasm, all of which lent such a unique tone to this anniversary event.

We are also determined to preserve the cultures of the businesses that have joined us. Our spirit of openness is rooted in our history and fosters mutual enrichment that benefits our teams.

Michel Baguenault,
Corporate Vice President, Human Resources and Communication

RESPONSIBILITY TO THE WORKFORCE

Quality social dialogue
bioMérieux has a tradition of meaningful social dialogue with employee representative bodies. This creates a constructive environment for employee relations with an emphasis on mutual respect in all interactions with social partners. In 2013, six company agreements were signed in France. An agreement provides for the harmonization of the employment status of AES-CHEMUNEX employees, marking an important step forward for the employees of this recently-acquired company, who gain access to new benefits.

Lastly, a working-from-home policy was formalized in 2013 to improve work-life-balance and rolled out in seven voluntary countries. This measure is intended for employees with a laptop computer whose jobs offer sufficient autonomy. In France, about 150 employees have signed up to take part in this initiative.

In addition, two company agreements on work organization have been signed in Italy.
**Giving young people a chance**

The “GPEC* Intergenerational Contract” was signed in France in 2013, demonstrating bioMérieux’s strong commitment to the employment of young people, in particular by developing different types of mentoring. Supporting young people as they enter the professional world is a genuine concern for bioMérieux. Relationships with schools and universities are at the heart of the Company’s recruitment policy to facilitate the integration of young graduates. In France, young people on work-study programs accounted for 4% of the workforce in 2013, with 143 under work-study or apprenticeship contracts, 19 with the international internship program (VIE), and five doctoral students. Over the course of the year, the Company welcomed about 350 young people, in particular for internships.

**Training, a strategic investment**

In 2013, 75% of Group employees took part in at least one training session. The average number of training hours per employee totaled 30 hours per person in France, 12 hours per person in the United States, and 49 hours per person in China.

Employee training is a priority in a sector where techniques and jobs are changing rapidly. bioMérieux’s training budget is five times more than the legal requirement, representing 5% of payroll expenditure. bioMérieux University’s in-house coaches and trainers provide technical and managerial training. To meet strategic and operational priorities, bioMérieux University created a Business Advisory Committee in 2013. It aims to determine the critical competencies that need to be strengthened within the organization as well as the associated development solutions. Specific courses are developed for each business function. Following the creation of an e-learning platform devoted to performance management, 51% of Group managers accessed the platform in 2013.

**Gender equality: focus on leadership**

Women represent half of bioMérieux’s workforce (50% as of December 31, 2013) and around 43% of managers are women. In keeping with agreements that have been regularly updated since 2003, the Company is committed to ensuring there is no gender discrimination in hiring and employment practices. In 2013, the role of women in the Group made progress on several fronts. For example, 29% of female employees are between ages 25 and 34, compared with 25% of men, illustrating an increase in female employees at the base of the age pyramid. In addition, a corporate program called “Women Ready for Leadership Diversity” (WoRLD) was rolled out globally to improve access to management positions for women.
Health, Safety and the Environment: a common approach worldwide

bioMérieux implements its Health, Safety and Environment policy internationally. The HSE management policy is laid out in a global manual signed by the Company’s Chairman and Chief Executive Officer. It describes the organization and implementation of HSE-related activities across all Company entities worldwide. All new employees receive HSE training upon their arrival.

The Company organizes its Health, Safety and Environment approach according to the principle of continuous improvement; programs are based on the ISO 14001 and OHSAS 18001 standards. For example, the Craponne (France) site has received OHSAS 18001 certification in 2013.

Application of the occupational health agreement signed in France in 2012 continued in 2013, addressing in particular hard working conditions and occupational risks.

The Company deploys prevention and protection programs that may exceed regulatory requirements. For example:

- A corporate HSE program on “minimum HSE operating requirements” applicable at all sites
- A program to harmonize occupational risk assessment for employees
- A program to harmonize the environmental analysis of activities
- A program for the management of personal protective equipment
- A program for the management and reporting of hazardous situations

In 2013, the corporate Health, Safety and Environment Department set up an intranet section devoted to HSE topics to share programs, best practices and HSE information with all Company employees.

Responsible procurement

In France, bioMérieux was one of the first signatories of the Responsible Supplier Relations Charter* and all buyers based in France received training on the Charter’s 10 commitments. bioMérieux is also a founding member of the Pas@pas Association, which promotes solidarity purchasing in connection with disability-friendly and socially inclusive companies.

In the United States, in compliance with the purchasing policy promoted by two major federal administrations that are customers of bioMérieux Inc., the Company has included veteran-owned, women-owned and minority-owned small businesses in its supplier portfolio according to an annually revised plan. The objectives established in connection with this plan were exceeded by 47% in 2013.

Fair and ethical business practices

Since 2003, bioMérieux has been a member of the United Nations Global Compact. It consequently implements specific initiatives each year to support the 10 principles of the Global Compact with respect to human rights, labor conditions, the environment and the fight against corruption.

bioMérieux respects a framework of principles, policies and procedures that reflect the highest ethical standards. In this way, it endeavors to achieve continuous improvement in the areas of working practices, human rights and anti-corruption actions.
A Global Code of Conduct applies to all bioMérieux employees and managers worldwide. It establishes rules of behavior and procedures to ensure ethical conduct and integrity in business relations. Distributed to all employees, the code is accessible at all times. It outlines what the Company expects of its employees, particularly concerning conflicts of interest and fighting corruption.

Within the broader framework of the Corporate Ethics and Compliance Program, a training program on the Global Code of Conduct is developed for each employee, with the objective to prevent, detect and respond to potential concerns or alerts concerning unethical behavior.

7,723* employees including 55% who work outside of France at December 31, 2013

50% of bioMérieux’s employees are women and women hold 43% of all management positions

Worldwide success for bioMérieux’s 50th anniversary:
57,779 people visited the dedicated website, 7,088 employees attended evening gala celebrations, and 9,421 photographs were collected to illustrate team spirit.

More than 1 out of 2 employees hold shares in bioMérieux

A booklet presenting the five pillars that unite all employees and are fundamental for the company was translated into six languages and distributed to all bioMérieux employees. These values include public health, social commitment, vision beyond borders, company roots and pioneering spirit.

328 jobs were created in 2013

bioMérieux was named the most attractive company in the Rhône-Alpes region, with the highest score nationally for all French regions combined. This distinction is part of an annual Employers Awards survey conducted for the website RégionsJob, the news weekly l’Express and the business monthly Le Journal des Entreprises, as well as the HR organization ANDRH**.

In 2013, bioMérieux’s U.S. subsidiary launched “Bravo,” an employee recognition program so that colleagues can applaud success stories, express appreciation and recognize performance. Posted on an intranet “Wall of Fame”, the program has met with resounding success.

19,000 hours of Manager Essentials training were provided in 2013 to Company managers as part of bioMérieux University’s offering, i.e., growth of nearly 10% from one year to the next.

172,025 hours of training were provided to bioMérieux employees worldwide, i.e., 23 hours per employee.

* full-time equivalent employees
** ANDRH: French National Association of Human Resources Directors

MILESTONES

Support to the Africa Mercy Hospital Ship of the Mercy Ships association

Transfer of the bioMérieux R&D laboratories on emerging pathogens in Lyon and Beijing (joint research unit created with the CAMS) to the Fondation Mérieux in the context of sponsorship
RESPONSIBILITY TO THE ENVIRONMENT

BIOMÉRIEUX GOES GREEN

bioMérieux is aware of the connections between health and the environment, and of the importance of maintaining a healthy environment to promote public health. With the aim of reducing its environmental footprint, bioMérieux adopted the BIOMÉRIEUX GOES GREEN approach in 2008, which focuses on five key areas: energy, water, paper, waste and emissions. The corresponding initiatives are rolled out through a network of 40 “green champions” (environmental correspondents) working at the Company’s sites and subsidiaries. To implement this environmental strategy, the roll-out of an environmental management system in compliance with the ISO 14001 international standard is continuing across 2009.

Support to different associations in the field of HIV
- AIDS Hilfe-Foundation (Germany)
- Santa Clara Foundation (Chile)
- Khao Yai (Thailand)
Optimized waste management

BioMérieux’s waste reduction policy is based on reducing waste at source and pursuing research and development of recycling and waste-to-energy streams. All the Group’s production sites are equipped with waste storage facilities, and several of them have reached waste management without landfilling. That is the case for the Grenoble, La Balme and Saint Vulbas sites in France, as well as the Basingstoke (U.K.) site and the German subsidiary. In 2013, the Durham site in North Carolina (U.S.) achieved the same status.

In 2013, the optimization of production equipment and the improvement of operator training resulted in:
- a 58% decrease in waste from the production of a range of culture media on the Lombard (U.S.) site;
- reduced quantities of discarded VITEK® 2 cards and filling pouches at the St. Louis (U.S.) site, amounting to total annual savings of 45 tons;
- a 6% decrease in waste from the production of ATB™ strips at the La Balme (France) site.

At the end of 2013, the percentage of recycled or incinerated waste with energy recovery had increased four points in comparison with 2012, to reach 74%.

Paying careful attention to water use

The Company uses water primarily for the formulation of its products and for refrigerated facilities, for controlled atmosphere areas, and as a coolant during manufacturing.

Water consumption decreased significantly in 2013 especially at two sites:

Marcy l’Etoile (France): a 9% reduction by discontinuing cooling towers and improving lawn maintenance management;
Durham (U.S.): a 6% reduction by equipping cooling towers with a water recovery system.

At the end of 2013, the ratio of water consumed to Company sales had decreased by around 18% over five years.

Aware of the potential impact of wastewater on health and the environment, bioMérieux strives to improve the quality of its wastewater. The Marcy l’Etoile and Craponne sites in France have invested in wastewater pre-treatment facilities.
More specifically, in line with its commitment to the fight against antimicrobial resistance, the Company implements separate systems for the collection of effluents from preparations containing antibiotics used for production or R&D. Such waste is disposed of through specific treatment facilities.

**Setting our sights on energy efficiency**

bioMérieux is committed to finding and progressively implementing solutions to reduce energy consumption to a low, or very low, level. In 2013, various projects focused on energy-consuming equipment have made or will make it possible to reduce associated consumption:

- Completion in 2013 of a program at the international logistics platform in Saint-Vulbas (France) for the replacement of the fluid management command system will lead to substantial energy savings in the future.
- Installation of a new boiler at the Florence (Italy) site resulted in a 22% reduction in the consumption of natural gas in 2013.

---

**Energy-saving initiatives:**

In 2013, bioMérieux set up a partnership with an “obligated” player to take advantage of opportunities to develop its energy-saving measures as part of the second period of the French energy saving certificates (ESC) scheme. Its various initiatives in this area have resulted in total savings of 4,756 MWh cumac*.

At the end of 2013, the Company’s energy consumption in relation to sales had decreased by 14% over 5 years.

bioMérieux also strives to encourage energy savings among its customers. For example, 55 products in the Etest® range no longer require negative temperature storage thanks to their eco-designed packaging.

---

In addition, bioMérieux seeks to use energy from renewable sources.

The Marcy l’Etoile and Craponne sites, two of the sites that consume the greatest amounts of electricity in the Company, have made a contractual commitment to using 50% certified “green” electricity in 2013-2015. Thanks to solar panels
set up in Durham (U.S.), this site produced and fed back into the local network 135,000 kWh of electricity in 2013. Lastly, 100% of the electricity purchased by the Austrian and Canadian subsidiaries is hydropower.

**Responsible use of paper**

bioMérieux’s sites and subsidiaries are seeking to reduce paper consumption. Incentives for greener printing practices and the adoption of new printing solutions have paid off, since paper consumption has been reduced by nearly 36% over five years in France. It was reduced by more than 19% for the same period in the United States.

More generally, the Company seeks to improve its processes by switching from paper to electronic formats. Since 2010, an Electronic Document Management system with an electronic review and approval circuit has been in place.

Similarly, paper instructions for use for bioMérieux reagents are gradually being phased out and replaced with electronic instructions for use that can be downloaded from the Company’s on-line technical library. As of the end of 2013, this solution covered five major ranges of reagents: TEMPO®, BacT/ALERT® and VIDAS® for Industry, as well as LyfoCults® and Etest®.

**Reducing atmospheric emissions**

In 2013, bioMérieux evaluated its Group carbon footprint through an assessment of greenhouse gas emissions taking into account emissions related to energy consumption, refrigerant gases, product transportation, business travel and employee commuting. The Company’s greenhouse gas emissions amounted to 171,000 metric tons of CO₂ equivalent.

bioMérieux is pursuing an active policy of reducing and optimizing business travel. By year-end 2013, eight sites had been equipped with telepresence facilities, which allow meetings to be conducted remotely via videoconferencing in conditions similar to those of face-to-face meetings.

The Group also encourages carpooling and the use of public transport whenever possible. Lastly, the home working policy, effective since the first quarter of 2013, also contributes to reducing employee commuting.

From a regional perspective, since October 2013, bioMérieux has been a partner of the Greater Lyon Energy-Climate Plan. This French region is where two of its largest production sites, Marcy l’Etoile and Craponne, are located. The Company thus confirms its commitment to contribute to the 2020 Greater Lyon objectives to reduce greenhouse gas emissions and energy consumption by 20%, and to increase the portion of energy from renewable sources to 20% of total energy consumed (in comparison to the year 2000).

Innovative solutions proposed to customers provide another means of reducing bioMérieux’s emissions.
The roll-out of the VILINK™ IT solution, initiated in 2009, continued in 2013. With VILINK™, remote interventions on bioMérieux instruments are possible for maintenance, incident resolution and software updates through a fast and secure connection. This solution avoids unnecessary travel by engineers working in the field and related emissions, and it enables faster problem resolution for customers of key product ranges (VITEK® 2, VITEK® MS, PREVI®, Isola, Myla®, VIDAS®, VIDAS 3®, TEMPO®, OBSERVA® and VIGIGUARD™).

### MILESTONES

- **€4 million**
  
  Invested in production sites in 2013 to preserve resources and prevent pollution.

- **74%: proportion of optimized waste**
  
  In 2013 in terms of materials and energy (i.e., waste that is recycled or incinerated with energy recovery).

- **18% reduction in water consumption**
  
  In relation to sales since 2009.

- **14% decrease in energy consumption**
  
  In relation to sales since 2009.

- **11% energy from renewable sources**
  
  In the Company’s total energy consumption in 2013.
The Board, chaired by Jean-Luc Belingard, met 5 times in 2013.

It is comprised of 9 members:

- Jean-Luc Bélingard - Chairman and CEO
- Alexandre Mérieux - Deputy CEO
- Alain Mérieux
- Michel Angé
- Philippe Archinard
- Harold Boël
- Marie-Hélène Habert
- Georges Hibon
- Michele Palladino

Committees of the Board of Directors

The Audit Committee met 6 times in 2013. It is comprised of Michel Angé, its chairman, Harold Boël and Georges Hibon.

The Human Resources Committee: Nominations and Compensation met twice in 2013. It is comprised of Alain Mérieux, its chairman, Marie-Hélène Habert, Michele Palladino and Michel Angé.
GENERAL MANAGEMENT

Strategy Committee
This committee is comprised of Alain Mérieux, Jean-Luc Belingard and Alexandre Mérieux.

Management Committee
The Management Committee, chaired by Jean-Luc Belingard, is responsible for implementing the company’s strategy decided by the Board of Directors. It meets once every three months.

As of December 31, 2013, it is comprised of:
1. Jean-Luc Bélingard - Chairman and CEO
2. Michel Baguenault - Corporate Vice-President, Human Resources and Communications
3. Thierry Bernard - Corporate Vice-President, Global Commercial Operations, Investor Relations & Executive VP Greater China
4. Nicolas Cartier - Corporate Vice-President, Industrial Microbiology Unit
5. Claire Giraut - Corporate Vice-President, Purchasing and Information Systems
6. François Lacoste - Corporate Vice-President, Immunoassay Unit and Quality
7. Marc Mackowiak - Chief Executive Officer, bioMérieux Inc.
8. Alexandre Mérieux - Deputy CEO and Corporate Vice-President, Microbiology Unit and Manufacturing and Supply Operations
9. Mark Miller - Chief Medical Officer
10. Alain Pluquet - Chief Technology Officer, Corporate Vice-President, Innovation and Systems Unit
11. Henri Thomasson - Chief Financial Officer
12. Stefan Willemsen - Corporate Vice-President, Business Development, Legal and Industrial Property

R&D Committee
In 2011, an R&D Committee was created. Chaired by Jean-Luc Bélingard, its role is to assess new innovative orientations and to optimize the resources to carry R&D projects through to a successful conclusion.
Sales for the year 2013 amounted to €1,588 million, compared with €1,570 million in 2012, representing a 4.6% increase at constant exchange rates and scope of consolidation. Sales growth in euros stood at 1.2%, impacted by currency effects.

In 2013, sales growth accelerated in North America and sales firmed up over the last two quarters in Western Europe. Emerging countries continued to present very attractive market dynamics, led in particular by the Asia-Pacific region, the primary contributor to growth in Group sales.

Over 70% of sales took place in clinical and industrial microbiology, two areas where bioMérieux holds the leading position globally. Moreover, in 2013, growth was rapid in industrial applications and in molecular biology, reflecting the successful integration of AES and ARGENE, two recently-acquired companies.

Operating income before non-recurring items reached €262 million, representing 16.5% of sales. It was virtually stable compared with 2012 (€260 million).

Net income amounted to €165 million, a 23% increase compared with 2012, bolstered in particular by a decrease in non-recurring operating expenses and a decrease in income tax expense.
Research and development expenses represented nearly 12% of sales, amounting to €186 million in 2013. This represents a nearly 10% increase at constant exchange rates and scope of consolidation, reflecting the ramp-up in preparations to launch new platforms.

Investments in 2013 represented €127 million. Industrial capital expenditure primarily concerned production capacity and output improvements, land acquisitions, and the construction and extension of industrial and R&D buildings. The Global ERP project also continued. In all, capital expenditure amounted to 8% of sales for the year.

Net cash amounted to €25 million at December 31, 2013, representing a sharp improvement over the course of the year in 2013. Anticipating the acquisition of BioFire in January 2014, the company placed a seven-year bond issue worth €300 million in October 2013.
## CONSOLIDATED INCOME STATEMENT

<table>
<thead>
<tr>
<th>IN MILLIONS OF EUROS</th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net Sales</strong></td>
<td>1,587.9</td>
<td>1,569.8</td>
</tr>
<tr>
<td>Cost of sales</td>
<td>-763.3</td>
<td>-755.6</td>
</tr>
<tr>
<td><strong>Gross profit</strong></td>
<td>824.6</td>
<td>814.2</td>
</tr>
<tr>
<td>Other operating income</td>
<td>28.2</td>
<td>26.1</td>
</tr>
<tr>
<td>Selling and marketing expenses</td>
<td>-283.2</td>
<td>-294.7</td>
</tr>
<tr>
<td>General and administrative expenses</td>
<td>-121.4</td>
<td>-114.3</td>
</tr>
<tr>
<td>Research and development expenses</td>
<td>-185.8</td>
<td>-171.0</td>
</tr>
<tr>
<td><strong>Total operating expenses</strong></td>
<td>-590.4</td>
<td>-580.0</td>
</tr>
<tr>
<td><strong>Operating income before non-recurring items</strong></td>
<td>262.4</td>
<td>260.4</td>
</tr>
<tr>
<td>Other non-recurring income (expenses)</td>
<td>-4.9</td>
<td>-25.4</td>
</tr>
<tr>
<td><strong>Operating income</strong></td>
<td>257.5</td>
<td>235.0</td>
</tr>
<tr>
<td>Cost of net financial debt</td>
<td>-3.9</td>
<td>-6.4</td>
</tr>
<tr>
<td>Other financial items</td>
<td>-10.1</td>
<td>-4.9</td>
</tr>
<tr>
<td>Income tax</td>
<td>-78.4</td>
<td>-89.4</td>
</tr>
<tr>
<td>Investments in associates</td>
<td>-0.4</td>
<td>0.0</td>
</tr>
<tr>
<td><strong>Net income of consolidated companies</strong></td>
<td>164.7</td>
<td>134.2</td>
</tr>
<tr>
<td>Attributable to the minority interests</td>
<td>0.4</td>
<td>-0.1</td>
</tr>
<tr>
<td><strong>Attributable to the parent company</strong></td>
<td>164.3</td>
<td>134.4</td>
</tr>
<tr>
<td>Basic net income per share</td>
<td>4.16 €</td>
<td>3.41 €</td>
</tr>
<tr>
<td>Diluted net income per share</td>
<td>4.16 €</td>
<td>3.41 €</td>
</tr>
</tbody>
</table>
## CONSOLIDATED BALANCE SHEET

<table>
<thead>
<tr>
<th>ASSETS (In millions of Euros)</th>
<th>NET 12/31/2013</th>
<th>NET 12/31/2012</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NON-CURRENT ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intangible assets</td>
<td>149.7</td>
<td>157.0</td>
</tr>
<tr>
<td>Goodwill</td>
<td>305.0</td>
<td>313.1</td>
</tr>
<tr>
<td>Property, plant and equipment</td>
<td>404.8</td>
<td>386.7</td>
</tr>
<tr>
<td>Financial assets</td>
<td>31.9</td>
<td>34.7</td>
</tr>
<tr>
<td>Investments in associates</td>
<td>0.4</td>
<td>0.0</td>
</tr>
<tr>
<td>Other non-current assets</td>
<td>24.5</td>
<td>29.6</td>
</tr>
<tr>
<td>Deferred tax assets</td>
<td>33.9</td>
<td>42.2</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>950.1</strong></td>
<td><strong>963.4</strong></td>
</tr>
<tr>
<td><strong>CURRENT ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inventories and work in progress</td>
<td>261.7</td>
<td>245.9</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>420.5</td>
<td>433.4</td>
</tr>
<tr>
<td>Other operating receivables</td>
<td>67.5</td>
<td>71.2</td>
</tr>
<tr>
<td>Tax receivable</td>
<td>7.7</td>
<td>20.7</td>
</tr>
<tr>
<td>Non-operating receivables</td>
<td>10.9</td>
<td>8.4</td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>428.0</td>
<td>65.6</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>1,196.2</strong></td>
<td><strong>845.4</strong></td>
</tr>
<tr>
<td>Assets held for sale</td>
<td>50.3</td>
<td>45.7</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td><strong>2,196.6</strong></td>
<td><strong>1,854.4</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LIABILITIES AND SHAREHOLDERS’ EQUITY (In millions of Euros)</th>
<th>NET 12/31/2013</th>
<th>NET 12/31/2012</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SHAREHOLDERS’ EQUITY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Share capital</td>
<td>12.0</td>
<td>12.0</td>
</tr>
<tr>
<td>Additional paid-in capital &amp; Reserves</td>
<td>1,084.5</td>
<td>1,007.0</td>
</tr>
<tr>
<td>Net income for the year</td>
<td>164.3</td>
<td>134.4</td>
</tr>
<tr>
<td><strong>TOTAL EQUITY BEFORE MINORITY INTERESTS</strong></td>
<td><strong>1,260.8</strong></td>
<td><strong>1,153.4</strong></td>
</tr>
<tr>
<td>Minority interests</td>
<td>6.5</td>
<td>6.8</td>
</tr>
<tr>
<td><strong>TOTAL SHAREHOLDERS’ EQUITY</strong></td>
<td><strong>1,267.3</strong></td>
<td><strong>1,160.2</strong></td>
</tr>
<tr>
<td><strong>NON-CURRENT LIABILITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net financial debt - long-term</td>
<td>304.6</td>
<td>9.8</td>
</tr>
<tr>
<td>Deferred tax liabilities</td>
<td>35.6</td>
<td>46.3</td>
</tr>
<tr>
<td>Provisions</td>
<td>73.3</td>
<td>103.0</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>413.4</strong></td>
<td><strong>159.1</strong></td>
</tr>
<tr>
<td><strong>CURRENT LIABILITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net financial debt - short-term</td>
<td>98.5</td>
<td>104.2</td>
</tr>
<tr>
<td>Provisions</td>
<td>10.2</td>
<td>11.0</td>
</tr>
<tr>
<td>Accounts payable</td>
<td>132.3</td>
<td>145.1</td>
</tr>
<tr>
<td>Other operating liabilities</td>
<td>222.8</td>
<td>217.9</td>
</tr>
<tr>
<td>Tax liabilities</td>
<td>19.7</td>
<td>20.2</td>
</tr>
<tr>
<td>Non-operating liabilities</td>
<td>19.6</td>
<td>23.8</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>503.2</strong></td>
<td><strong>522.2</strong></td>
</tr>
<tr>
<td>Liabilities related to assets held for sale</td>
<td>12.7</td>
<td>13.0</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY</strong></td>
<td><strong>2,196.6</strong></td>
<td><strong>1,854.4</strong></td>
</tr>
</tbody>
</table>
## CONSOLIDATED CASH FLOW STATEMENT

### CASHFLOW STATEMENT (in millions of euros)

<table>
<thead>
<tr>
<th>Description</th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net income of consolidated companies</td>
<td>164.7</td>
<td>134.2</td>
</tr>
<tr>
<td>Adjustments</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Investments in associates</td>
<td>0.4</td>
<td>0.0</td>
</tr>
<tr>
<td>- Cost of net financial debt</td>
<td>3.9</td>
<td>6.4</td>
</tr>
<tr>
<td>- Other financial items</td>
<td>10.0</td>
<td>4.9</td>
</tr>
<tr>
<td>- Current income tax expense</td>
<td>78.4</td>
<td>89.4</td>
</tr>
<tr>
<td>- Operating depreciation and provisions on assets</td>
<td>90.9</td>
<td>94.4</td>
</tr>
<tr>
<td>- Non-recurring items</td>
<td>4.9</td>
<td>25.4</td>
</tr>
<tr>
<td>EBITDA (before non-recurring items)</td>
<td>353.3</td>
<td>354.8</td>
</tr>
<tr>
<td>Other non current operating gains/losses (w/o exceptional depreciations, assets losses and capital gains/losses)</td>
<td>1.7</td>
<td>-2.9</td>
</tr>
<tr>
<td>Other financial items (w/o accruals &amp; disposal of financial assets)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Operating provisions for risks and contingencies</td>
<td>-6.2</td>
<td>8.0</td>
</tr>
<tr>
<td>Change in fair value of financial instruments</td>
<td>4.1</td>
<td>-0.4</td>
</tr>
<tr>
<td>Share-based payments</td>
<td>0.8</td>
<td>-2.5</td>
</tr>
<tr>
<td>Elimination of other gains and losses without any impact on cash or operations</td>
<td>-7.2</td>
<td>1.7</td>
</tr>
<tr>
<td>Increase in inventories</td>
<td>-26.3</td>
<td>-32.0</td>
</tr>
<tr>
<td>Increase of requirements in accounts receivable</td>
<td>-9.5</td>
<td>6.5</td>
</tr>
<tr>
<td>Decrease in accounts payable</td>
<td>-9.6</td>
<td>6.0</td>
</tr>
<tr>
<td>Decrease of other operating working capital</td>
<td>5.3</td>
<td>-6.7</td>
</tr>
<tr>
<td>Increase in operating working capital</td>
<td>-40.1</td>
<td>-26.2</td>
</tr>
<tr>
<td>Other non operating working capital</td>
<td>-0.3</td>
<td>3.0</td>
</tr>
<tr>
<td>Change in non-current assets</td>
<td>3.7</td>
<td>1.4</td>
</tr>
<tr>
<td>Other cashflows from operation</td>
<td>-36.7</td>
<td>-21.8</td>
</tr>
<tr>
<td>Income tax paid</td>
<td>-68.9</td>
<td>-76.2</td>
</tr>
<tr>
<td>Net cash flow from operations</td>
<td>240.5</td>
<td>258.5</td>
</tr>
<tr>
<td>Purchase of property, plant and equipment</td>
<td>-131.1</td>
<td>-127.4</td>
</tr>
<tr>
<td>Proceeds on fixed asset disposals</td>
<td>4.6</td>
<td>8.2</td>
</tr>
<tr>
<td>Purchase of financial assets / Disposals of financial assets</td>
<td>-1.7</td>
<td>-12.9</td>
</tr>
<tr>
<td>Impact of changes in the scope of consolidation</td>
<td>-0.4</td>
<td>1.7</td>
</tr>
<tr>
<td>Net cash flow from (used in) investment activities</td>
<td>-128.6</td>
<td>-130.4</td>
</tr>
<tr>
<td>Increase in capital</td>
<td>0.2</td>
<td>0.0</td>
</tr>
<tr>
<td>Purchases and proceeds of treasury stocks</td>
<td>-0.3</td>
<td>0.8</td>
</tr>
<tr>
<td>Dividends to shareholders</td>
<td>-38.7</td>
<td>-38.7</td>
</tr>
<tr>
<td>Dividends to minority interests</td>
<td>0.0</td>
<td>-0.5</td>
</tr>
<tr>
<td>Cost of net financial debt</td>
<td>-3.9</td>
<td>-6.4</td>
</tr>
<tr>
<td>Change in confirmed financial debt</td>
<td>293.3</td>
<td>-11.4</td>
</tr>
<tr>
<td>Net cash flow from (used in) financing activities</td>
<td>250.6</td>
<td>-56.2</td>
</tr>
</tbody>
</table>

## NET CHANGE IN CASH AND CASH EQUIVALENTS

<table>
<thead>
<tr>
<th>Description</th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net cash and cash equivalents at the beginning of the year</td>
<td>52.5</td>
<td>-19.2</td>
</tr>
<tr>
<td>Impact of currency changes on net cash and cash equivalents</td>
<td>-0.1</td>
<td>-0.2</td>
</tr>
<tr>
<td>Net change in cash and cash equivalents</td>
<td>362.5</td>
<td>71.9</td>
</tr>
<tr>
<td>Net cash and cash equivalents at the end of the year</td>
<td>414.9</td>
<td>52.5</td>
</tr>
</tbody>
</table>
THE BIOMÉRIEUX SHARE

SHARE PRICE PERFORMANCE IN 2013*

* Indexes rebased on bioMérieux’s stock price as at December 31, 2012 (€72.00)

BREAKDOWN OF CAPITAL
AS AT DECEMBER 31, 2013

THE BIOMÉRIEUX SHARE

Listed on July 6, 2004, the bioMérieux share is part of the following indexes: CAC Mid 60®, SBF 120®, CAC Mid & Small®, CAC All-tradeable® and CAC All-Share®.

The Company is listed on the compartment A of Eurolist and is eligible for the Deferred Settlement Service (SRD).

bioMérieux is also part of certain sustainability indexes: Gaia Index 2012/2013, FTSE4Good Index, Ethibel EXCELLENCE Register and Ethibel PIONEER Register.

At the end of December 2013, the closing price of the bioMérieux share was €76.27 euros and the market capitalization reached 3 billion euros.

6,108,288 shares were traded on the NYSE Euronext platform in 2013.

2014 CALENDAR
OF EVENTS

- January 22nd: 2013 Q4 business review
- March 19th: 2013 results
- April 23rd: 2014 Q1 business review
- May 28th: Shareholders meeting
- July 17th: 2014 Q2 business review
- September 3rd: 2014 first-half results
- October 22nd: 2014 Q3 business review

CONTACT RELATIONS INVESTISSEURS

Isabelle Tongio
Phone: 33 (0)4 78 87 22 37
Email: investor.relations@biomerieux.com
The Reference Document approved by the AMF is available upon request or on our Web site: www.biomerieux-finance.com
### Analyte
Substance measured in an analytical procedure.

### Antibiotic Susceptibility Testing
Determines the growth of a bacterium in the presence of antibiotics and classifies it as susceptible, resistant or intermediate.

### Biomarker/marker
Any indicator (nucleic acids, enzymes, metabolites and other types of molecules: histamines, hormones, proteins, etc.) present in the body or excreted by it as a biological response to a physiological or pathological condition. A biomarker can make it possible to identify the presence, the effect and/or the measurement of specific phenomena, such as:
- the rapid or early detection of a disease, before the first symptoms appear,
- the progression of a disease,
- the impact of a drug or treatment.

### Blood culture
An essential blood test involving the microbiological culture of blood and used to detect bloodstream infections. It is carried out by taking a sample of venous blood, which is then cultured to reveal the presence or absence of pathogenic microbes.

### Cytometry
General name for a group of biological methods used to measure various parameters of cells including cell size and morphology.

### Enumeration
Counting how many microbes (bacteria or fungi) are present in a sample.

### Enterobacteria
A family of Gram-negative bacilli (bacteria), which are aerobic or anaerobic (they can live and reproduce with or without oxygen).

### Flow cytometry
A technique that consists of passing a stream of cells, particles or molecules at high speed through a laser beam. The light re-emitted (by diffusion or fluorescence) enables the population to be classified and sorted according to several criteria.

### Healthcare Associated Infection
An infection that patients acquire during the course of receiving treatment for other conditions within a hospital or healthcare setting.

### Immunoassay
Diagnostic test based on an antigen/antibody reaction, enabling the detection of infectious agents (bacteria, viruses, parasites) and pathogen markers.

### In vitro Diagnostics
Analysis of biological samples (urine, blood, etc.) performed outside the human body.

### Listeria
A genus of bacteria that can cause listeriosis, an infectious disease that is potentially serious in newborn babies, pregnant women and individuals with low resistance.
**Mass spectrometry**
Technique used to identify a molecule and determine its chemical structure by analyzing the mass and the charge of its ions.

**Microbiology**
Study of microorganisms. bioMérieux uses culture-based microbiology methods for the growth of bacteria from biological fluids, food and pharmaceutical samples. The bacteria are subsequently identified and their susceptibility to antibiotics tested in certain cases.

**Molecular Biology**
Technique that can detect a bacterium, virus, yeast, parasite or a biomarker through the presence of DNA or RNA genetic sequences in a sample.

**Multiplex**
A multiplex assay simultaneously measures multiple analytes (dozens or more) in a single run, as opposed to an assay that measures a single analyte.

**Pathogen**
A microbe which causes or has the potential to cause an infectious disease.

**PCR (Polymerase Chain Reaction)**
Molecular biology technology for *in vitro* amplification of genetic sequences, used to copy known DNA or RNA sequences in large quantities (by an order of magnitude of a billion) from an initially small quantity. This technology is particularly useful for detecting the presence of viruses.

**Phage Recombinant protein**
Bacteriophage tail protein that has been obtained by a biological process. Bacteriophages: highly specific viruses that only infect bacteria. They are used for the targeted capture of bacteria and to isolate them from a sample.

**Salmonella**
Salmonella belong to the *Salmonella* genus of *Enterobacteriaceae*. They cause two types of illness: food-borne gastroenteritis (salmonellosis), and typhoid/paratyphoid fevers.

**Sepsis**
A widespread infection characterized by the presence of bacteria in the bloodstream (fungi, viruses and parasites can also cause sepsis) and the deterioration of the patient’s general condition as a result of the infection (host response).

**Syndrome approach**
Medical approach based on analyzing a syndrome (i.e. a set of symptoms) and, with a single test, identifying the disease-causing organisms responsible for this syndrome, whether they are viruses, bacteria, fungi or parasites.

**Theranostics**
The association of a diagnostic test with a therapy. The foundation of personalized medicine.
In 2013, bioMérieux celebrated both its 50th anniversary and a remarkable entrepreneurial adventure at the service of public health worldwide. With key dates noted over the pages, this year’s annual report summarizes the main steps that have marked the development of the Group, its product offering, as well as its capacity to innovate and its international development.

www.biomerieux50.com

Thanks to all bioMérieux employees who contributed to the Annual Report photos.